Advertisement
News
Advertisement

New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies

Sat, 03/19/2011 - 9:34am
Bio-Medicine.Org

KING OF PRUSSIA, Pa., March 19, 2011 /PRNewswire/ -- CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin G (IgG) following administration to be simulated with a high degree of accuracy and precision. The new PK model provides a novel means of simulating the mechanism by which SC IgG is transported after it is injected into the subcutaneous tissue. Data from the model, which was developed by CSL Behring in collaboration with researchers at Cardiff University, Keele University, and Prism Ideas Ltd, were described in both a poster presentation and an oral presentation at the 2011 American Academy of Allergy, Asthma and Immunology annual meeting.

The current understanding of the clinical implications of SC versus intravenous (IV) dosing of IgG in primary immunodeficiency (PI) patients is limited. In addition, little is known about where SC IgG travels within the body after it is administered and how long it remains there. This information defines IgG's pharmacokinetic (PK) profile and could affect the volume and frequency of IgG dosing for PI patients.

"At CSL Behring we are continually searching for and identifying ways of improving treatment for patients with primary immunodeficiencies," said Martin Bexon, M.D., Program Director, Global Clinical Research and Development at CSL Behring. "This model increases our knowledge of how SC IgG is distributed throughout the body and has the potential to help us further optimize a dosing schedule that balances the convenience and therapeutic value of Hizentra for PI patients."

The new PK model, presented at this meeting in both a poster (Bexon et al; Poster 46; Session 2203) and an oral presentation (Jolles et al; Session 4602) describes a complex system of continuous interactions between extravascular (tissue) and intravascular (blood) compartments that help

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading